Plasma lipoproteins, hemostasis and thrombosis

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 386-394

  Griffin, J H ^a   Fernandez J A ^a   Deguchi, H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Glucosylceramide; Glycolipid; Lipoprotein; Protein C; Prothrombinase

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; CARDIOLIPIN; ENZYME; GLOBOTRIAOSYLCERAMIDE; GLUCOSYLCERAMIDE; GLYCOLIPID; GLYCOSPHINGOLIPID; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLETHANOLAMINE; PROCOAGULANT; PROTEIN C; PROTHROMBIN; THROMBIN; TRIACYLGLYCEROL;

ANTICOAGULATION; BLOOD CLOTTING; CONFERENCE PAPER; DOWN REGULATION; DRUG MECHANISM; ENZYME SUBSTRATE; HEMOSTASIS; HYPERLIPIDEMIA; LIPID OXIDATION; PLASMA; PLASMA CHARACTERISTICS; PLASMA FACTOR; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SURFACE PROPERTY; THROMBOSIS;

EID: 0034927113     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616236     Document Type: Conference Paper

References (99)

1. Lipoproteins and the haemostatic system in atherothrombotic disorders
2. Postprandial lipaemia and haemostatic factors
3. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men
4. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface
5. Activation of coagulation factor VII during alimentary lipemia
6. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency
7. Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia.
8. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, concentraion, and risk of coronary heart disease in men
9. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma
10. Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action "Clotart"
11. Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated Factor VII
12. Antiatherothrombotic properties of statins. Implications for cardiovacular event reduction
13. Current perspectives on statins
14. Vastatins inhibit tissue factor in culture human macrophages. A novel mechanism of protection against atherothrombosis
15. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
16. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
17. Statin drugs and dietary isoprenoids as antithrombotic agents
18. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
19. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
20. Herditary thrombophilia. Chapter 127
21. Hypercholesterolemia as a risk factor for deep-vein thrombosis
22. Increased lipoprotein (a) is an important risk of factor venous thromboembolism in childhood
23. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism
24. Plasma glucosylceramide deficiency as potential risk factor venous thrombosis and modulator of anticoagulant protein C pathway
25. Vascular-bed-specific hemostasis and hypercoagulable states
26. The endothelium and thrombosis
27. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier
28. Waterfall sequence for instrinsic blood clotting
29. The coagulation cascade: Initiation, maintenance, and regulation
30. The molecular basis of blood coagulation
31. Formation of the fibrin clot: The balance of procoagulant and inhibitory factors
32. Tissue factor pathway inhibitor and the revised theory of coagulation
33. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis
34. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C
35. Identification, cloning, and regulation of a novel endothelial cell proteinC/activated protein C receptor
36. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
37. The anticoagulant properties of a modified form of protein S
38. Binding of protein S to factor Va associated with inhibition of prothrombinase that is the independent of activated protein C
39. Protein S binds to an inhibits factor Xa
40. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa
41. Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial cell matrix: An independent anticoagulant function of protein S in plasma
42. Inhibition of the intrinsic factor X activating complex by protein S: Evidence for a specific binding of protein S to factor VIII
43. Efficacy and safety of recombinant human activated protein C for severe sepsis
44. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation
45. Cloning and characterization of a cDNA coding for the lipoprotein- associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
46. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a)
47. The tissue factor pathway: How it has become a "prima ballerina"
48. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor
49. Phosphatidylethanolamine incorporation into vesicles selectively enhances Factor Va inactivation by activated protein C
50. Lipid oxidation enhances and function of activated protein C
51. Cardiolipin enhances protein C pathway anticoagulant activity
52. Vitamin K-dependent proteins bind to very low-density lipoproteins
53. Association between coagulation factors VII and X with triglyceride rich lipoproteins
54. Activation of coagulation factor VII during alimentary lipemia
55. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes
56. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E
57. Binding of prothrombin to chyle chylomicrons: Effects of temperature and calcium ions, and role of surface phospholipids
58. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma
59. Role of activation of the coagulation Factor VIII in interaction with vWf, phospholipid, and functioning within the Factor Xase complex
60. Plasma lipoproteins enhance tissue-independent factor VII activation
61. High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C
62. Resistance to activated protein C as a basis for venous thrombosis
63. Anticoagulant protein C pathway defective in majority of thrombophilic patients
64. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden thrombophilia study
65. Mutation in blood coagulation factor V associated with resistance to activated protein C
66. Activated protein C resistance caused by Arg506Gln mutation in factor Va
67. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V
68. Activated protein C resistance in ischemic stroke not due to factor V arginine506→glutamine mutations
69. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease
70. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state
71. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
72. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
73. Activated protein C resistance in patients with peripheral vascular disease
74. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease
75. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia
76. Inhibition of arterial thrombus formation by ApoA1 Milano
77. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation
78. Glucosylceramide synthase and glycosphingolipid synthesis
79. Functional rafts in biological membranes
80. Functions of lipid rafts in biological membranes
81. Looking at lipid rafts?
82. Structure and function of sphingolipid- and cholesterol-rich membrane rafts
83. Direct detection of activated protein C in blood from human subjects
84. Identification of divalent metal ion-dependent inhibition of activated protein C by α2-macroglobulin and α2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin and plasmin
85. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
86. Protein C activation following coronary artery occlusion in the in situ porcine heart
87. Brain-specific protein C activation during carotid artery occlusion in humans
88. Cardiopulmonary bypass and activation of antithrombotic plasma protein C
89. Activation of protein C in vivo
90. Anti-thrombotic effects of thrombin-induced activation of endogenous protein C in primates
91. The thrombin paradox
92. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system
93. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of triglyceride-rich lipoproteins
94. A potential basis for the thrombotic risks associated with lipoprotein(a)
95. Lipoprotein(a), plasmin modulation, and atherogenesis
96. Lipoprotein(a) and atherosclerosis
97. High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms
98. Low serum cholesterol as a risk for hemorrhagic stroke in men: A community-based mass screening in Okinawa, Japan
99. Different risk factors for different stroke subtypes: Association of blood pressure, cholesterol, and antioxidants